Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 1;8(8):9655-61.
eCollection 2015.

Recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chondrosarcomatous differentiations: a rare case and literature review

Affiliations
Review

Recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chondrosarcomatous differentiations: a rare case and literature review

Pengcheng Zhu et al. Int J Clin Exp Pathol. .

Abstract

Selective tyrosine kinase inhibitor (TKI) targeting KIT and PDGFRA is the frontline therapy for metastatic and unresectable GIST patients. Some initially responsive patients experience tumor progress because of secondary drug resistance, and some cases can develop heterogeneous differentiation. Here we report a rare case of recurrent retroperitoneal extra-GIST with rhabdomyosarcomatous and chondrosarcomatous differentiation with TKI therapy after surgical tumorectomy. Histology, immunohistochemistry, and mutational analysis were performed on primary and recurrent samples. The current case represents the first report of a recurrent retroperitoneal extra-GIST harboring mixed morphologic phenotypes of rhabdomyosarcoma and chondrosarsoma after TKI treatment. The dual differentiation can represent diagnostic pitfall.

Keywords: Extragastrointestinal stromal tumor; chondrosarcoma; heterogeneous differentiation; rhabdomyosarcom; tyrosine kinase inhibitor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Primary tumor specimen of retroperitoneal extra-GIST shows spindle-shaped cells of a high dense cellularity, hyperchromasia, and nuclear atypia, and a high mitotic activity (A. ×100; B. ×400).
Figure 3
Figure 3
Recurrent tumor showing classic morphology of extra-GIST (A. ×100) and heterogeneous rhabdomyosarcomatous and chondrosarcomatous differentiation (B. ×100; C, D. ×200).
Figure 2
Figure 2
Primary tumor of retroperitoneal extra-GIST was confirmed by immunopositivity for CD117and DOG1 with high Ki-67 labeling index, but immunonegativity for CD34.
Figure 4
Figure 4
Recurrent tumor with dual transdifferentiation was confirmed by immunopositivity for CD117 in classic GIST area, desmin, myogenin in rhabdomyosarcomatous area and S-100 in chondrosarcomatous area.

References

    1. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269. - PMC - PubMed
    1. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577–585. - PubMed
    1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580. - PubMed
    1. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710. - PubMed
    1. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056. - PubMed

MeSH terms

LinkOut - more resources